Impact of L-DOPA treatment of patients with Parkinson's disease on mononuclear subsets and phagocytosis in the peripheral blood

Folia Neuropathologica

Volumn 51, Issue 2, 2013, Pages 127-131

  Hurny, Artur ^a   Michałowska Wender, Grazyna ^b,c   Wender, Mieczysław ^c  

^a Regional Hospital for Neurological and Psychiatric Diseases   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Apoptosis; L DOPA; Mononuclear subset; Parkinson's disease; Phagocytosis

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CD3 ANTIGEN; FAS ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD CELL; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; EARLY DIAGNOSIS; EXTRAPYRAMIDAL SYNDROME; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; MONONUCLEAR PHAGOCYTE; PARKINSON DISEASE; PHAGOCYTOSIS; TREATMENT DURATION;

EID: 84879810957     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: 10.5114/fn.2013.35955     Document Type: Article

References (14)

1. Bas J, Calopa M, Mestre M, Mollevi DG, Cutillas B, Ambrosio S, Buendia E. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol 2001; 113: 146-152. (Pubitemid 32008680)
2. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray- Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119: 182-192.
3. Calopa M, Bas J, Callen A, MestreM. Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol Dis 2010; 38: 1-7.
4. Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH, Jin BK. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 2010; 43: 225-232.
5. Członkowska A, Kurkowska-Jastrzebska I, Członkowski A, Peter D, Stefano GB. Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Med Sci Monit 2002; 8: 165-177.
6. Fischer U, Piotrowska K, Korlak J, Członkowska A. The immunological status in Parkinson's disease. Med Lab Sci 1991; 48: 196- 200.
7. Fischer U. Does Parkinson's disease have an immunological basis? The evidence and its therapeutic implications. BioDrugs 2001; 15: 351-355.
8. Fischer U. Selected aspects of immunological disorders in Par - kinson disease. Neurol Neurochir Pol 2004; 38: S63-66.
9. Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory pro - cesses in Parkinson's disease. Parkinsonism Relat Disord 2005; 11 Suppl 1: S9-S15. (Pubitemid 40693572)
10. Jellinger KA. Cell death mechanism in Parkinson's disease. J Neural Transm 2000; 107: 1-29. (Pubitemid 30077039)
11. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24: 574-576.
12. Pfeiffer RF. Neuroinflammation and Parkinson disease: the si lent battleground. Neurology 2009; 73: 1434-1435.
13. Rugbjerg K, Friis S, Ritz B, Schernhammer ES, Korbo L, Olsen JH. Autoimmune disease and risk for Parkinson disease. Neurology 2009; 73: 1462-1468.
14. Smith PF. Inflammation in Parkinson's disease: an update. Curr Opin Investig Drugs 2008; 9: 478-484. (Pubitemid 351677901)